New York Life Investment Management LLC Sells 4,325 Shares of Artivion, Inc. (NYSE:AORT)

New York Life Investment Management LLC cut its position in shares of Artivion, Inc. (NYSE:AORTFree Report) by 13.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,136 shares of the company’s stock after selling 4,325 shares during the quarter. New York Life Investment Management LLC owned about 0.07% of Artivion worth $411,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. New York State Common Retirement Fund increased its position in shares of Artivion by 25.0% during the third quarter. New York State Common Retirement Fund now owns 15,009 shares of the company’s stock worth $228,000 after buying an additional 2,999 shares during the period. Barclays PLC grew its holdings in Artivion by 17.7% in the third quarter. Barclays PLC now owns 23,025 shares of the company’s stock worth $348,000 after purchasing an additional 3,458 shares during the period. Illinois Municipal Retirement Fund acquired a new stake in Artivion in the third quarter worth $395,000. Mesirow Financial Investment Management Inc. acquired a new stake in Artivion in the third quarter worth $251,000. Finally, Silverleafe Capital Partners LLC acquired a new stake in Artivion in the third quarter worth $152,000. 83.32% of the stock is currently owned by institutional investors and hedge funds.

Artivion Trading Up 1.0 %

NYSE:AORT opened at $17.16 on Friday. The company has a current ratio of 4.86, a quick ratio of 3.43 and a debt-to-equity ratio of 1.14. The stock has a market capitalization of $703.56 million, a price-to-earnings ratio of -28.60 and a beta of 1.64. The firm has a fifty day simple moving average of $17.79 and a two-hundred day simple moving average of $16.23. Artivion, Inc. has a 12 month low of $11.44 and a 12 month high of $19.00.

Insider Buying and Selling at Artivion

In other Artivion news, VP John E. Davis sold 13,562 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $18.00, for a total value of $244,116.00. Following the transaction, the vice president now directly owns 128,733 shares of the company’s stock, valued at $2,317,194. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Artivion news, VP John E. Davis sold 13,562 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $18.00, for a total value of $244,116.00. Following the transaction, the vice president now directly owns 128,733 shares of the company’s stock, valued at $2,317,194. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 21,229 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $18.00, for a total transaction of $382,122.00. Following the completion of the transaction, the senior vice president now directly owns 133,520 shares in the company, valued at $2,403,360. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,289 shares of company stock valued at $936,212. Corporate insiders own 6.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Artivion in a report on Thursday, December 7th.

View Our Latest Analysis on Artivion

About Artivion

(Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.

Further Reading

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORTFree Report).

Institutional Ownership by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.